Re: Arena Pharmaceuticals to Present New Preclinical Atopic Dermatitis Data for Etrasimod at the European Society for Dermatologic Research Annual Meeting
The conclusion part seemed pretty clear to me: "Etrasimod
significantly reduced the activation and expansion of immune cells
after challenge in the dLN and ear skin. Notably, the dose-dependent
reduction of immune cells in ear skin correlated with improvements in
disease. This data encourages further study of etrasimod as a novel
therapy for AD."